Current views on the functions of interleukin-17A-producing cells in atherosclerosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Theme Issue
Immunology of atherosclerosis

Issue: 2011: 106/5 (Nov) pp. 753-992
Pages: 787-795

Current views on the functions of interleukin-17A-producing cells in atherosclerosis

M. Butcher (1), E. Galkina (1)

(1) Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia, USA


Atherosclerosis, cytokines, immune response, interleukin-17, T helper cells


Multiple components of the immune response are involved in the initiation, progression and persistence of atherosclerosis. Interleukin (IL)-17A is produced by a broad variety of leukocytes and plays an important role in host defense. IL-17A is also involved in the pathology of several autoimmune diseases mainly via the regulation of chemokine expression and leukocyte migration to the site of inflammation. There is an increasing body of evidence indicating an association between elevated levels of IL-17A and cardiovascular diseases. Interestingly, this IL-17A-dependent response occurs in parallel with the Th1-dominant immune response during atherogenesis. To date, the precise role of IL-17A+ cells in atherosclerosis is controversial. Several studies have suggested a pro-atherogenic role of IL-17A via the regulation of aortic macrophage numbers, Th1-related cytokines and aortic chemokine expression. However, two studies recently described anti-inflammatory effects of IL-17A on mouse plaque burden via possible regulation of aortic VCAM-1 expression and T cell content. Furthermore, an initial study using IL-17A-deficient mice demonstrated that IL-17A affects the immune composition and inflammatory phenotype of the aortic wall; however, no effects were observed on atherosclerosis. Further studies are necessary to fully address the role of IL-17A and other IL-17 family members in atherosclerosis.

You may also be interested in...

Gijs H. M. van Puijvelde; Eva J. A. van Wanrooij; Arnaud D. Hauer; Paula de Vos; Theo J. C. van Berkel; Johan Kuiper

Thromb Haemost 2009 102 2: 223-230


Online Supplementary Material

See also Steffens

J. Shalhoub (1, 2), L. E. Viiri (1), A. J. Cross (1), S. M. Gregan (1), D. M. Allin (2), N. Astola (1), I. J. Franklin (2), A. H. Davies (2), C. Monaco (1)

Thromb Haemost 2016 115 5: 1064-1072


Theme Issue Article to Theme Issue "Platelets, Inflammation and anti-inflammatory drugs in ACS and CAD"

K. A. L. Müller (1, 2), M. Chatterjee (1), D. Rath (1), T. Geisler (1)

Thromb Haemost 2015 114 3: 498-518